InconclusiveReview/Other2025
EE165 Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System
Classification Results
AI Classification
InconclusiveFine-tuned Classification
N/A